> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Accepts Tecentriq sBLA for Priority Review
- URL: https://www.fdaweb.com/fda-accepts-tecentriq-sbla-for-priority-review/
- Published: 2021-08-03T12:00:00.000Z
- Updated: 2026-09-14T17:09:01.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5149856

FDA has accepted a Genentech sBLA and granted priority review for Tecentriq (atezolizumab) as adjuvant treatment following surgery and platinum-based chemotherapy for specified people with non-small cell lung cancer. The company [says](https://www.gene.com/media/press-releases/14924/2021-08-02/fda-grants-priority-review-to-genentechs?ref=fdaweb.com) FDA is reviewing the application under the real-time oncology review pilot program and is expected to decide by 12/1.

Genentech says the application is based on disease-free survival results from an interim analysis of the Phase 3 IMpower 010 study, the only Phase 3 study of a cancer immunotherapy to demonstrate positive results in the adjuvant lung cancer setting.

Tecentriq is described as a monoclonal antibody designed to bind with the PD-L1 protein expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. It is indicated for treating non-small cell lung cancer under certain specified conditions.